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Abstract 
Background: Numerous studies have shown the neurotoxicity of anesthetic 
substances in different age groups. This toxicity is often associated with damage 
or apoptosis of nerve cells that can lead to various diseases, including 
Alzheimer's, behavioral changes and transient and even persistent cognitive 
changes. In this study, it was attempted to evaluate the cytotoxic conditions 
following the use of three common anesthetic drugs (bupivacaine, 
dexmedetomidine and dexamethasone) by providing a suitable substrate. 
Methods and Materials: Mice (Mus musculus) with the same weight (22 to 30 
gr) were used for assessment of neurotoxicity in Bupivacaine, 
Dexmedetomidine and Dexamethasone. Unilateral femoral nerve injections 
were done; animals were randomly divided into four groups: control, 
bupivacaine alone, "bupivacaine + dexmedetomidine" and "bupivacaine + 
dexamethasone". After 24 hours, the mice were sacrificed and the femoral 
nerve removed. Hematoxylin-eosin tissue staining was used to evaluate 
changes in the effects of the drugs, and nerve samples were extracted to assess 
the expression of TLR4 and caspase3. Protein expression level was checked 
between different groups using Western blot technique. 
Results: The bupivacaine + dexamethasone group showed better outcomes in 
terms of cytotoxicity than bupivacaine + dexmedetomidine (p=0.568); also, 
bupivacaine + dexamethasone reduced neurotoxicity risk (P=0.431). 
Conclusion: Bupivacaine+dexamethasone leeds to better outcomes in terms 
of neurotoxicity compared with bupivacaine+dexmedetomidine.  
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myocardial infarction, and pulmonary embolism, and 
other complications, such as postoperative nausea and 
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vomiting, are often an integral part of all anesthesia 
procedures (1). Numerous studies have challenged the 
neurotoxicity risks of anesthetic agents in animal 
studies which might lead to neurological cell damage; 
including Alzheimer's disease, behavioral and 
cognitive changes (2). The most important receptors 
involved in the pathway of brain development during 
anesthetic drug exposure are N-Methyl-D-Aspartate 
(NMDA) and Gamma-Aminobutyric Acid (GABA) 
(3-5). Anesthetic drugs that impair these receptors 
drive the cellular pathway of neuro-apoptosis. Given 
the limitations of the cellular repair in central nervous 
system, it is mandatory to reduce this risk (6). 
Bupivacaine is one of the amide anesthetics 
used in neural block and neuraxial anesthesia that acts 
mainly through the sodium channel block with varying 
reports of effects on neurologic tissue cells (7-9). This 
drug has been shown to induce apoptotic effects in 
various studies (10). Amongst them, the effects on 
Schwann cells are one of the most prominent effects 
(11). Dexmedetomidine is an alpha-2 agonist that is 
recently used in a number of patient groups (12). Many 
studies show that the drug alone has safer profile 
regarding neurotoxicity issues (13). So that 
concomitant use with isoflurane reduces the rate of 
neuronal cell death (14). The majority of the studies 
have claimed this protective effect is due to the issue 
that it does not affect the GABA or NMDA receptor 
pathway (15). Dexamethasone is a type of 
corticosteroid medication (16). Corticosteroids have 
also been reported to have anti-apoptotic effects (17). 
Toll-like receptors are found on the surface of 
dendritic cells, macrophages, neutrophils, mucosal 
cells, and other innate immune cells and identify their 
own agents from other alien cells (18). Meanwhile, 
TLR4 is originally introduced as an endotoxin detector 
(LPS) and a cellular content-related injury marker such 
as DNA, RNA, and the cytoplasm (19). Previous 
studies have demonstrated the role of this protein in 
neural cell damage and the formation of oxygen free 
radicals. Therefore, TLR4 level assay can be a 
determining factor in cytotoxicity (20).  
The caspase3 protein is a member of the 
cysteine-aspartic acid protease (caspase) family (21). 
Sequential activation of caspases plays a central role in 
the execution phase of cell apoptosis (22). 
This study was designed to investigate the 
neurotoxic effects of bupivacaine when used as local 
anesthetic, alone or with either dexamethasone or 




Mice (Mus musculus) with a similar weight 
(22 to 30 gr) used for neurotoxicity evaluation of 
Bupivacaine, Dexmedetomidine, and 
Dexamethasone. Mice were kept and used according 
to the companion animal ethics (23).  
Injections into the femoral nerve were 
performed unilaterally and rats were randomly divided 
into four groups (in each group, four mice) of control 
(Ketamine 300 µl+ Xylazine 100 µl), bupivacaine 
alone (Ketamine 300µl+ Xylazine 100µl +bupivacaine 
2mg/kg), bupivacaine in combination with 
dexmedetomidine (Ketamine 300 µl+ Xylazine 100 µl 
+bupivacaine 2 mg/kg +Dex 1 mg/kg) and in group 4, 
bupivacaine was injected with dexamethasone 
(Ketamine 300 µl+ Xylazine 100 µl +bupivacaine 2 
mg/kg +Dexa 5 mg/kg). 
After 24 h, mice sacrificed using gas CO2 and 
the femoral nerve removed. Hematoxylin-eosin 
staining used to evaluate changes in the effects of the 
drugs on isolated nerve tissues, and nerve samples 
extracted to measure TLR4 expression.  
The protein then extracted by 
radioimmunoprecipitation assay buffer (RIPA buffer). 
The expression levels of the proteins evaluated by 
electrophoresis and western blotting. At this stage, 20-
40 μg of protein used for Western blotting. ImageJ 
software used to detect and analyze images from 
Western blotting. 
This study reviewed and approved by the 
Research Ethics Committee of Shahid Beheshti 
University of Medical Sciences, with the registration 
code of IR. SBMU. RETECH.REC.1397.1030. 
Results 
The expression of TLR4 and caspase3 (as 
contributing factors to apoptosis induction and 
toxicity) were compared with GAPDH (as a house-
keeping gene and baseline) in four different groups. As 
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can be seen in fig 1, the expression index of caspase 3 
biomarker was presented based on the amount and 
thickness of the band produced on SDS gel following 
Western blot technique (Figure 1). 
Figure 2 shows the electrophoresis results of the 
proteins extracted on the gel. This figure presents the 
qualitative range of affinity of the target protein 
(caspase3 marker) to the standard GAPDH index. 
Figure 3 presents the quantification of TLR4 
biomarker based on the amount and density of the band 
produced on SDS gel, followed by the Western blot 
technique. This table presents the results of TLR4 
protein extraction 24 h after injection into the rat 
femoral nerve compared to the standard GAPDH index 
for the four groups (control, bupivacaine, bupivacaine 
+dexamethasone and bupivacaine+dexmedetomidine). 
Figure 4 shows the electrophoresis results of the 
proteins extracted on the gel. This table presents the 
qualitative range of affinity of the target protein (TLR4 
marker) by group and extraction site compared to the 
 
Figure 1. Diagram (P. Value) of caspase3 expression compared to GAPDH in rat femoral nerve (24 h after injection) in 
four groups (control, bupivacaine, bupivacaine + dexamethasone and bupivacaine + dexmedetomidine). 
 
Figure 2. Qualitative comparison of caspase3 protein expression in rat femoral nerve for four groups (control, bupivacaine, 
bupivacaine + dexamethasone and bupivacaine + dexmedetomidine) compared to standard GAPDH index protein. 
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standard GAPDH index.  
Discussion 
The results of the present study emphasized the 
neuro-cytotoxic damage of these drugs. For this 
purpose, two molecular markers of apoptosis initiation 
(TLR4 and caspase3) evaluated as an indicator of 
cellular damage induced by the use of drugs used on 
rat femoral nerves (24 h after injection). Thus, the 
expression of both the TLR4 and caspase3 markers 
under the combined use of bupivacaine + 
dexmedetomidine and bupivacaine + dexamethasone 
has the low affinity with the baseline index (GAPDH). 
Simply put, the use of bupivacaine in combination with 
two other drugs (dexmedetomidine and 
dexamethasone) has caused less damage to mouse 
neurons. However, the combination of bupivacaine 
with dexamethasone (p=0.568 and p=0.431) showed 
relatively better conditions in terms of cytotoxicity 
than the combination of bupivacaine with 
dexmedetomidine (p=0.768 and p=0.725) (Figs. 1 and 
 
Figure 3. Diagram (P. Value) of TLR4 expression compared to GAPDH in rat femoral nerve (24 h after injection) in four 
groups (control, bupivacaine, bupivacaine + dexamethasone and bupivacaine + dexmedetomidine). 
 
Figure 4. Qualitative comparison of TLR4 protein expression in rat femoral nerve for four groups (control, bupivacaine, 
bupivacaine + dexamethasone and bupivacaine + dexmedetomidine) compared to standard GAPDH index protein. 
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3). 
The damages that occur following the use of 
all kinds of anesthetic materials are caused by 
activation of microglia and the presence of astrocytes 
and by the involvement of neurons. Previously, the 
association between inflammation in the nervous 
system and neurodegenerative diseases has been 
proven to increase the risk of Alzheimer's disease by 
pro-inflammatory markers. This process is likely to 
cause brain damage after transient ischemia, either 
primary or secondary. 
Gözi̇l R et al. in 2002 introduced bupivacaine as 
the drug of choice for neural obstruction. According to 
their observations, this drug, while less damaging, 
accelerates the regeneration process (24). In 2016, 
O'Connor and colleagues reported that dexamethasone 
alone (at a dose of 10 μm or higher) had protective 
effects on neurons. Therefore, concurrent use of 
adrenergic substances such as dexmedetomidine may 
reduce neuronal cell damage (25). Wu et al. (2014) 
published a study on the synergistic effect of 
dexmedetomidine and ropivacaine on the inhibition of 
neuron-astrocyte activity. According to their study, 
concomitant use of both drugs increased the quality of 
anesthesia and decreased astrocyte activity (26). As a 
result, they suggested that the combination of the two 
drugs would improve conditions to improve the effect 
of anesthesia and reduce inflammation in the central 
nervous system. 
Conclusion 
Concomitant administration of bupivacaine 
with dexmedetomidine and dexamethasone reduces 
bupivacaine neurotoxicity. This is while, concomitant 
use of bupivacaine+dexamethasone has led to better 
conditions than concomitant use of 
bupivacaine+dexmedetomidine in reducing 
neurotoxicity. 
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